TACE before surgery for large liver cancer
Part of Cancer, Digestive system clinical trials.
This trial combines a procedure called TACE (which blocks the blood supply to the tumor) with surgery to remove a large liver tumor. It is for people newly diagnosed with a large liver cancer that hasn't spread and can be completely removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of liver cancer called hepatocellular carcinoma (HCC).
- Your liver tumor is larger than 10 cm (about 4 inches).
- You are between 18 and 75 years old.
- The cancer has not spread into major blood vessels or to other parts of the body.
- Your liver is healthy enough for surgery to remove all of the tumor, and you have enough healthy liver left after surgery.
- You have not had liver cancer before (this is your first time).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments for people with large liver tumors. One is a liver artery chemotherapy infusion and the other is a chemo-embolization procedure. The study will see which approach works better.
This trial tests whether a liver-directed treatment called TACE (transarterial chemoembolization) after surgery can help prevent liver cancer from coming back in people with high-risk features.
This trial tests a combination of treatments for liver cancer that cannot be removed with surgery. It uses a procedure to block the tumor's blood supply plus two drugs that help the immune system fight the cancer. This may help shrink tumors and slow the disease.
This trial studies a treatment approach (a combination given through the liver) for people with early liver cancer that can be surgically removed but has a high chance of coming back. It may help reduce the risk of recurrence after treatment.
This trial tests whether combining TACE (a liver-targeted chemo procedure) with two medicines—an immune “checkpoint” drug and a blood-vessel blocking drug—can control unresectable hepatocellular carcinoma. It’s designed for people who can’t have surgery or curative ablation, and who still have reasonably strong liver and overall health.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.